Johannes Jacob Pieter Kastelein, Chief Scientific Officer at NewAmsterdam Pharma, sold NAMS on Aug 24, 2026
Data as of Oct 16
▼ SELL$3.4M125,000 shares at $26.91Johannes Jacob Pieter Kastelein Chief Scientific OfficerNAMS NewAmsterdam Pharma Co N.V.
- Traded
- Aug 24, 2026
- Disclosed
- Aug 25, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
NAMS since disclosure
−27.5%
after the sale
Similar stocks (XLV) since disclosure
+0.8%
XLV — its sector index fund
Change in closing price from Aug 25, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.